Despite the limited anti-tumor effect induced by the PI3K-mTOR inhibitors single agents or in combination with dacomitinib, downstream inhibition of the PI3K/AKT/mTOR pathway was observed in all of the arms containing a PI3K-mTOR inhibitor (Figure 4A-4F): all models exhibited pS6 inhibition and the LGSOC and LADC models also exhibited pAKT inhibition. The gene discussed is AKT1; the disease is neoplasm.